...
首页> 外文期刊>Current vascular pharmacology >Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study
【24h】

Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study

机译:切换二肽基肽酶-4抑制剂对Tofogliflozin,一种选择性抑制剂的钠 - 葡萄糖分类剂2改善了2型糖尿病患者的心肌 - 踝血管指数评估的动脉僵硬度:试验研究

获取原文
获取原文并翻译 | 示例
           

摘要

Background: We have found that anagliptin, a dipeptidyl peptidase-4 inhibitor (DPP-4) significantly ameliorates arterial stiffness in Type 2 Diabetes Mellitus (T2DM) patients compared with an equivalent hypoglycaemic agent, glimepiride. However, it remains unclear whether switching DPP-4 inhibitors to tofogliflozin, a selective inhibitor of Sodium-Glucose Cotransporter 2 (SGLT2) improves arterial stiffness in T2DM patients.
机译:背景:与当量的低血糖药物,胶质素酰亚的子相比,我们发现一只二肽基肽酶-4抑制剂(DPP-4)显着改善2型糖尿病(T2DM)患者的动脉僵硬度。 然而,仍然不清楚是否将DPP-4抑制剂转换为Tofogliflozin,一种钠葡萄糖分类剂2(SGLT2)的选择性抑制剂改善了T2DM患者的动脉僵硬度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号